DMRA

23.2304.40%
TS

Tariq Sethi

Co-Founder

Prof. Tariq Sethi, B.Sc. M.A. M.D. Ph.D. Frcp is Chief Physician Scientist at Astra Zeneca and Emeritus Professor at Kings College London. He served as Chief Scientific Officer of Oncimmune Holdings Plc since October 1, 2019. Prof. Sethi is Co-Founder and served as Member of the Clinical Advisory Board- IPF of Damora Therapeutics, Inc. (formerly known as Galecto, Inc.) (aka Galecto Biotech AB). Prof. Sethi was Head of Respiratory Medicine Kings Health Partners / Kings College London and was previously Professor of Respiratory and Lung Cancer Biology at the University of Edinburgh. His research interests are on the interaction between inflammation and lung cancer, focusing on the regulation of proliferation and apoptosis by growth factor and integrin mediated signalling. He is an author of numerous scientific papers and has edited books on lung cancer. Prof. Sethi is also on the editorial board of THORAX. He is a researcher, clinician and entrepreneur with over 35 years of combined academic and industry experience in the field of immunology, inflammation and Lung Cancer. He was Chief Physician Scientist, Vice President in the Clinical Discovery Unit AstraZeneca and Emeritus Professor of Respiratory Medicine King's College London and had been Vice President in AstraZeneca's Respiratory Immunology Autoimmunity Translational Medicine Unit. He was educated at Cambridge and London Universities followed by junior hospital jobs in London. He gained a PhD at the Imperial Cancer Research Fund London and was subsequently appointed lecturer in Medicine at Edinburgh University. As an MRC Travelling Fellow, he worked at the Scripps Research institute California, returning to Edinburgh as a Wellcome Trust Senior Research Leave Fellow.

Positions